Loading...
Bring together diverse assay data—from bulk RNA-seq and ATAC-seq to ChIP-seq and more—into a unified multi-omics experiment for in-depth insights into cellular processes and disease mechanisms. Multi-omics integration on Pluto Bio brings together disparate data types—from chromatin accessibility to gene expression and protein levels—into a unified analysis platform. By leveraging integrated pipelines, our system not only simplifies the merging of complex datasets but also enhances your ability to detect subtle patterns that drive biological processes. Whether you’re exploring disease mechanisms or mapping intricate regulatory networks, Pluto Bio’s multi-omics suite provides the insights needed to propel your research forward.
Pluto Bio’s multi-omics platform empowers researchers to merge data from diverse experimental techniques—ranging from RNA-seq and ATAC-seq to proteomics and beyond—into one integrated workflow. This holistic view provides unprecedented insights into the intricate networks governing cellular function.
Discover howDive deep into the layers of biological information with tools designed to align and analyze multiple omics datasets. Our streamlined platform simplifies complex data integration, enabling faster hypothesis testing and a more complete understanding of disease mechanisms and cellular biology.
Explore our toolsGain actionable insights by visualizing and interpreting multi-omics data without the steep learning curve. Pluto Bio’s intuitive interface allows you to navigate seamlessly between data types, transforming raw information into a coherent, decision-driving narrative.
Learn more
End fragmented data workflows with a secure, collaborative hub for multi-omics research.
How Pluto Accelerates Collaboration and Insights Across Multi-Omics Data
The analysis bottleneck holding teams back
A collaborative platform that helps translational research teams turn multi-omics data into insight, alignment, and impact.
Funding led by new investor Kickstart, with continued support from Silverton Partners and other investors
Discover how proteomics empowers translational scientists to uncover disease biomarkers, identify novel drug targets, and optimize clinical decisions.
Compare top bioinformatics platforms—Pluto Bio, Partek Flow, Basepair, and Rosalind—to find the best fit for your NGS data analysis needs. Assess supported assays, analyses, visualizations, and collaboration features.
Explore how multi-omics integrates diverse datasets like RNA-seq, ATAC-seq, and ChIP-seq to unlock biological insights, accelerate drug discovery, and drive personalized therapies. Learn more about its impact on cancer research and target identification.
Discover how Pluto’s multi-omics pipelines accelerate target validation in drug discovery. Learn how integrated platforms streamline the path from omics data to validated therapeutic targets.
Discover top alternatives to Rosalind for bioinformatics and computational biology. Explore platforms like Pluto Bio, BaseSpace, GenePattern, and more to find the right solution for your research needs.
Discover how multi-omics revolutionizes drug discovery by integrating genomics, proteomics, and more to reveal complex disease networks, enabling precise target validation and accelerated breakthroughs.
Learn how Nimbus Therapeutics is simplifying Multi-Omics Data Analysis: Nimbus Therapeutics' Success with Pluto Bio
Multi-omics has emerged as a transformative technology in drug discovery. Layering genomics, transcriptomics, proteomics and other molecular analyses in a single experiment can provide deep biological insight and identify new therapeutic targets. However, developers face challenging data integration and analysis to get the most out of multi-omics data. Here, we explore how bioinformatics is key to unlocking the full potential of multi-omics and transforming drug discovery.
Learn how Nimbus Therapeutics is simplifying multi-omics data analysis and accelerating small molecule drug discovery with Pluto’s bioinformatics platform
Pluto Bio partners with Wyss Institute Brain Targeting Program on novel target discovery. Leading institute to use Pluto’s target discovery platform to integrate -omics data, literature, and other evidence in their discovery of brain-targeting shuttles for drug delivery that can help revolutionize the treatment of brain diseases.
Products that Count is a 501(c)3 nonprofit that helps everyone build great products. It celebrates product excellence through coveted Awards that inspire 500,000+ product managers and honor great products and the professionals responsible for their success.
We're thrilled to announce that Pluto has been selected as one of 20 companies in the 2024 cohort of the BioTools Innovator Accelerator, the first accelerator dedicated to supporting life science tools.